Molecular Partners

SWX:MOLN · CH0256379097

BiotechnologySmall

360° View

Value31

Price/Sales25

Price/Earnings37

Price/Book41

Dividend Yield1

Growth44

Revenue Growth1

Profit Growth32

Capital Growth45

TSR 52w45

Safety18

Leverage63

Liquidity4

Refinancing25

Combined6

Sentiment7

Analyst Opinions19

Pro Holdings23

Opinion Changes50

Market Pulse29

Profile

CountrySwitzerland

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeSWX

Founded2004

Employees135

Websitemolecularpartners.com

ISINCH0256379097

Last UpdateApr 2, 2026

Index & Theme

ImmunologyStem Cell TherapyHematologyOncologyBiotechnologyMedicalPharmaceutical

Description

Molecular Partners AG is a clinical-stage biotechnology company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address. The company has programs in various stages of prec…

Analysis

Molecular Partners's 360° View rank of 1 places it among the weakest overall — better than 1% of its true peers.

It's growing slowly (44) and on the expensive side (31). On safety it is highly leveraged (18), and the market shows skeptical sentiment (7). Taken together, its Combined rank of 6 reads as among the weakest overall.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Molecular Partners with its peers

BeOne Medicines

SHH:688235

CountrySwitzerland

IndustryBiotechnology

SizeX-Large

Full Stock Analysis →

Kamada

NSQ:KMDA

CountryIsrael

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Heidelberg Pharma

GER:HPHA

CountryGermany

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Alkermes

NSQ:ALKS

CountryIreland

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

MoonLake Immunotherapeutcs

NAQ:MLTX

CountrySwitzerland

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

MindMaze Therapeutics Holding

SWX:MMTX

CountrySwitzerland

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →